• AAL-993: From VEGFR Potency to Assay Design

  2026-09-20

  AAL-993 is a selective VEGF receptor inhibitor with a distinctive VEGFR-2/3 potency profile. This article explains how to use it as a causal validation tool alongside network pharmacology in tumor angiogenesis research.

• CFDA SE Cell Tracer Kit: Practical Guide

  2026-09-19

  The CFDA SE Cell Tracer Kit provides persistent fluorescent labeling for cell proliferation studies, cell lineage tracing, and live-cell tracking. It is appropriate when covalent labeling must remain detectable for several days, but not when reversible marking, rapid dye clearance, or immediate physiological readouts are required.

• WST-8 Glucose Uptake Assay Kit Guide

  2026-09-18

  The WST-8 Glucose Uptake Assay Kit is a non-radioactive glucose uptake assay based on 2-deoxyglucose conversion, NADPH generation, and 450 nm formazan detection. Product information reports a working linearity of 10–500 μM under stated assay conditions, supporting quantitative cellular glucose metabolism studies.

• Beyond Viability: Measuring Cancer Drug Responses

  2026-09-18

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent dimensions of an in vitro drug response. The framework encourages cancer researchers to combine endpoint and time-course measurements so that cytostatic effects are not mistaken for cell killing.

• Balsalazide in Active Ulcerative Colitis: Evidence Review

  2026-09-17

  This 2009 review examined balsalazide as a colon-targeted 5-aminosalicylate prodrug for mild-to-moderate active ulcerative colitis. Its central finding was that bacterial activation in the colon supports sustained 5-ASA delivery, with clinical evidence for remission induction, rapid symptom improvement, and tolerability comparable to other oral 5-ASA therapies.

• EdU Imaging Kits (Cy3): S-Phase Detection

  2026-09-17

  EdU Imaging Kits (Cy3) provide antibody-free detection of DNA synthesis during S phase through copper-catalyzed click chemistry. The 5-ethynyl-2'-deoxyuridine imaging kit supports fluorescence microscopy and flow cytometry while preserving morphology and antigen-accessible epitopes.

• Pazopanib in ATRX-Aware Glioma Assays

  2026-09-16

  Pazopanib (GW-786034) offers a powerful way to study RTK dependence, angiogenesis inhibition, and genotype-specific drug response in glioma models. This guide translates ATRX-focused evidence into assay decisions that distinguish cell-autonomous toxicity from vascular effects.

• PD 173074: FGFR1 Workflows for Cancer Research

  2026-09-16

  PD 173074 enables pathway-resolved testing of FGFR1-driven growth, fibroblast-mediated drug rescue, and VEGFR2-linked angiogenesis. This practical guide translates ESCC microenvironment findings into dose-finding, co-culture, signaling, and troubleshooting workflows.

• Better In Vitro Cancer Drug Response Evaluation

  2026-09-15

  Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. By separating growth inhibition from cell killing, the work provides a more interpretable framework for cancer research, assay design, and drug-response profiling.

• Sunitinib Workflows for RCC Resistance Research

  2026-09-15

  Build more informative Sunitinib experiments by pairing RTK pathway inhibition with apoptosis, cell-cycle, angiogenesis, and metabolic readouts. This workflow translates recent renal cell carcinoma resistance findings into practical combination assays, controls, and troubleshooting decisions.

• CH 223191: Dissecting AhR Context in Toxicology

  2026-09-14

  CH 223191 is an aryl hydrocarbon receptor antagonist for separating harmful AhR activation from context-dependent physiological signaling. This article connects dioxin toxicology with microbiota–tryptophan–AhR biology and translates that distinction into better assay design.

• Gut-Brain Cholinergic Signaling in Seizure Control

  2026-09-14

  Jia et al. identify a gut-vagus-brain cholinergic circuit through which Bacteroides fragilis suppresses seizures, connecting microbial composition with colonic ChAT-positive cells, vagal transmission, and brain excitability. Mouse experiments and a randomized pediatric clinical trial provide complementary evidence for microbiota-targeted antiseizure strategies, while also highlighting the need for careful mechanistic and translational validation.

• Bsa I (RNase-free): Practical DNA Cleavage Guide

  2026-09-13

  Bsa I (RNase-free) provides sequence-directed DNA cleavage for cloning and other molecular biology workflows where RNA contamination must be minimized. It is intended for research use with validated reaction conditions, not for diagnostic, clinical, or medical applications.

• Phalloidin (B7678): F-Actin Workflow Guide

  2026-09-12

  Phalloidin (B7678) is a cyclic heptapeptide toxin used to stabilize and visualize filamentous actin in fixed, permeabilized cells, tissue sections, and cell-free assays. It is suitable for static cytoskeleton visualization, but not for live-cell imaging or experiments that require reversible actin remodeling.

• E. coli Uracil-DNA Glycosylase (UDG) Protocol

  2026-09-11

  E. coli Uracil-DNA Glycosylase (UDG), SKU K1107, removes uracil residues from single- and double-stranded DNA and can support PCR product contamination elimination when uracil-containing carryover DNA is part of the workflow. It is inactive toward RNA and oligonucleotides shorter than six bases, and it is intended only for scientific research rather than diagnostic or medical use.

8364 records 1/558 page Next 12345 下5页 Last page